Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era

Prognosis for patients with refractory/relapsed (R/R) diffuse large B-cell lymphoma (DLBCL) is poor. Immune-based therapeutic treatments such as CD19 Chimeric Antigen Receptor (CAR) T cell therapies have dramatically changed the treatment landscape for R/R DLBCL leading to durable remissions in ~ 50...

Descripción completa

Detalles Bibliográficos
Autores principales: Atallah-Yunes, Suheil Albert, Robertson, Michael J., Davé, Utpal P., Ghione, Paola, Perna, Fabiana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198279/
https://www.ncbi.nlm.nih.gov/pubmed/35720352
http://dx.doi.org/10.3389/fimmu.2022.901365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198279/
https://www.ncbi.nlm.nih.gov/pubmed/35720352
http://dx.doi.org/10.3389/fimmu.2022.901365

Ejemplares similares